$NTLA News

Intellia Therapeutics To Highlight Data From Global Phase 3 HAELO Clinical Trial Of Lonvo-Z In Hereditary Angioedema In Late-Breaking Oral Presentation At EAACI Annual Congress 2026

Intellia Therapeutics Announces That Data From The Global Phase 3 HAELO Clinical Trial Of Lonvo-Z In Hereditary Angioedema Will Be Presented At The European Academy Of Allergy & Clinical Immunology Annual Congress 2026

Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight

Bernstein Maintains Market Perform on Intellia Therapeutics, Raises Price Target to $17

HC Wainwright & Co. Maintains Buy on Intellia Therapeutics, Lowers Price Target to $25

Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Canaccord Genuity Maintains Buy on Intellia Therapeutics, Lowers Price Target to $49

Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price Target

Intellia Therapeutics Q1 EPS $(0.81) Beats $(0.90) Estimate, Sales $15.048M Beat $14.793M Estimates

Intellia Therapeutics Q1 EPS $(0.81) Beats $(0.90) Estimate, Sales $15.048M Beat $14.793M Estimate

Canaccord Genuity Maintains Buy on Intellia Therapeutics, Raises Price Target to $58

Goldman Sachs Maintains Sell on Intellia Therapeutics, Raises Price Target to $9

Citizens Maintains Market Outperform on Intellia Therapeutics, Raises Price Target to $30

Morgan Stanley Maintains Equal-Weight on Intellia Therapeutics, Raises Price Target to $15

Intellia Therapeutics And Wall Street Continue To Play Their D&D Game - Data And Doubt

Intellia Therapeutics Commences $150M Common Stock Offering

Intellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema - Slideshow

Intellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema Transcript

Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $30

Baird Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13